Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMBTDZL)

Drug Name
3-Phenyl-pyrrolidine Drug Info
Synonyms
3-Phenylpyrrolidine; 936-44-7; 3-Phenyl-pyrrolidine; Pyrrolidine, 3-phenyl-; (Pyrrolidin-3-yl)benzene; CHEMBL75207; PRRFFTYUBPGHLE-UHFFFAOYSA-N; F2189-0088; 3-phenyl-pyrolidine; 3-phenyl-pyrollidine; 4-phenyl-pyrrolidine; PubChem22374; BAS 03334576; AC1MK0OA; SCHEMBL4122; AC1Q1H4Y; (+/-)-3-phenyl-pyrrolidine; 3-phenylpyrrolidine, AldrichCPR; KS-00001OYR; CTK3I6515; DTXSID60389848; MolPort-000-006-168; HMS1704P05; 3AAX-0-0; BBL008865; ANW-54854; SBB010168; KM3208; BDBM50144660; STK006609; AKOS000674061; AKOS016051772; MCULE-5600189216
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
3146743
CAS Number
CAS 936-44-7
TTD Drug ID
DMBTDZL

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Dopamine D2 receptor (D2R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [2]
Haloperidol DM96SE0 Delirium Approved [3]
Perphenazine DMA4MRX Schizophrenia 6A20 Approved [4]
Perazine DM2AOTZ Psychotic disorder 6A20-6A25 Approved [5]
Domperidone DMBDPY0 Gastrointestinal disease DE2Z Approved [6]
Levodopa DMN3E57 Parkinson disease 8A00.0 Approved [7]
Quetiapine DM1N62C Anorexia nervosa cachexia 6B80 Approved [8]
Pimozide DMW83TP Schizophrenia 6A20 Approved [9]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [10]
Iloperidone DM6AUFY Schizophrenia 6A20 Approved [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Inhibitor [1]

References

1 Regioselective synthesis of 3-aryl substituted pyrrolidines via palladium catalyzed arylation: pharmacological evaluation for central dopaminergic and serotonergic activity, Bioorg. Med. Chem. Lett. 7(3):241-246 (1997).
2 The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
3 Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
4 CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
5 Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
6 Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
8 Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
9 [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
10 Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
11 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.